48P Real-world clinical utility of next-generation sequencing ctDNA for patients with advanced lung squamous cell carcinoma by García Pardo de Santayana, M., García de Herreros, M., Laguna, J.C., Nahorski, M., Howarth, K., Olmedo Garcia, M.E., Garrido Lopez, P., Gorría, T., Albarran Artahona, V.M., Arcocha, A., Teixido, C., Reguart Aransay, N., Vinolas Segarra, N., Auclin, E., Vasseur, D., Planchard, D., Besse, B., Leighl, N., Mezquita, L.

Get full text

158P Neoadjuvant treatment in stage III NSCLC: Comparison with NADIM 2 trial as a gold standard by Casas, F., Redondo, M.G. Antelo, Sanchez-Lorente, D., Reyes, R., Martinez, D., Lucena, C., Vollmer, I., Cases, C., Mollá, M., Boada, M., Roig, M. Parera, Acosta, S. Castillo, Muñoz, S., Centella, C. Urbano, Guirao, A., Cobo, A., Benegas, M., Leon, F., Clavell, C., Segarra, N. Vinolas

Get full text

178P Germline testing in non-small cell lung cancer (NSCLC): Real-world impact of the discovery of germline pathogenic variants (PGV) in the INHERITY LC (ILC) study by Montes, J.C. Laguna, Lastra, R., Gomez, O. Higuera, Berjaga, M. Zurera, Pellitero, A. Moratiel, Menao-Guillen, S., Arruebo, M., Potrony, M., Sole, X., Arcocha, A., Moreno, L., Sainz, L. Gutierrez, Teixido, C., Segarra, N. Vinolas, De-Castro, J., Casado, M.D. Isla, Mezquita, L.

Get full text

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC by Arce-Lara, C., Arriola, E., Brunsvig, P., Carcereny, E., Domine, M., Dragnev, K., Felip, E., García Campelo, R., Krebs, M., Paz-Ares, L., Ponce Aix, S., Spicer, J., Trigo, J.M., Vinolas Segarra, N., Holt, R., Micklem, D., Brown, A., Chisamore, M., Lorens, J.

Get full text

Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma by Solá, C., Mallafré, J., Solórzano, L. Mendoza, Segarra, A., Daniels, M., Vinolas, N., Alcaraz, A., Solé, M., Alvarez, R., Biete, A., Estapé, J.

Get full text